ID   ZEC-134
AC   CVCL_VT85
DR   CCRID; 4201PAT-CCTCC00911
DR   Wikidata; Q98136466
RX   Patent=CN105969734A;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016108.
CC   Population: Chinese.
CC   Doubling time: ~60 hours (Patent=CN105969734A).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): Patent=CN105969734A
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D12S391: 21,22
ST   D13S317: 8
ST   D16S539: 10,12
ST   D18S51: 14
ST   D19S433: 15
ST   D21S11: 29,30
ST   D2S1338: 23
ST   D3S1358: 18
ST   D5S818: 15
ST   D6S1043: 20
ST   D7S820: 10,12
ST   D8S1179: 10
ST   FGA: 25
ST   Penta D: 9,13
ST   Penta E: 15
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 14,18
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 29-06-23; Version: 9
//
RX   Patent=CN105969734A;
RA   Su D., Xiong L., Mao W.-M., Pei G.-Q., Ying L.-S., Xie Z.-H., Wu J.-Z.;
RT   "Esophageal cancer cell line and application thereof.";
RL   Patent number CN105969734A, 28-Sep-2016.
//